# Exploring the effects of tinzaparin and cisplatin on lung cancer cells in vitro

**Authors:** Julia Held, Marc A. Schneider, Beatriz Martinez-Delgado, Bin Liu, David S. DeLuca, Elena Korenbaum, Sabina Janciauskiene, Thomas Muley

PMC · DOI: 10.1186/s12935-026-04214-5 · Cancer Cell International · 2026-02-05

## TL;DR

This study shows that tinzaparin, a type of heparin, affects lung cancer cells differently depending on the cell type, influencing their growth and response to chemotherapy.

## Contribution

The study reveals cell-specific effects of tinzaparin on lung cancer cell proliferation and drug sensitivity, highlighting its complex role.

## Key findings

- Tinzaparin increased proliferation in some NSCLC cell lines but reduced it in 2427 T cells.
- Transcriptomic analysis showed CTSL and HMOX1 as consistently altered genes in response to tinzaparin.
- Tinzaparin partially counteracted cisplatin's effects on cell proliferation and apoptosis in certain cell lines.

## Abstract

Low molecular weight heparins (LMWH) are widely used to prevent or treat cancer- and thrombosis-related conditions. However, their direct effects on cancer cells remain unclear.

Nine non-small cell lung cancer (NSCLC) cell lines (H1437, H2126, H661, H1299, H1563, H1975, H1573, 2106 T, 2427 T) were treated with tinzaparin (50 IU/ml, ~ 76.9 µM), cisplatin (15 µg/ml), or a combination. We assessed cell viability, proliferation, colony formation, and intracellular lipid droplet accumulation. RNA sequencing was performed on two adenocarcinoma (H1437, H1563) and two squamous cell carcinoma (2106 T, 2427 T) lines to explore transcriptomic changes.

Tinzaparin increased proliferation in H1437, H2126, H1299, and H661 cells, but slightly reduced it in 2427 T cells. Colony formation was reduced only in 2427 T, with no effect in other lines despite some showing increased proliferation. Tinzaparin modestly increased viability in 2427 T cells and partially counteracted cisplatin-induced proliferation inhibition in H1573 and apoptosis in H1437 and H2126. Lipid droplet formation was unaffected. Transcriptomic analysis showed variable responses across cell lines, with only CTSL (Cathepsin L) and HMOX1 (Heme Oxygenase 1) consistently altered by tinzaparin.

Tinzaparin affects proliferation, viability, colony formation, and drug sensitivity in NSCLC cells in a cell type–specific manner. These findings highlight the complex actions of LMWHs on lung cancer cells and underscore the need for further mechanistic studies to understand their potential impact on cancer progression and therapy.

The online version contains supplementary material available at 10.1186/s12935-026-04214-5.

## Linked entities

- **Genes:** CTSL (cathepsin L) [NCBI Gene 1514], HMOX1 (heme oxygenase 1) [NCBI Gene 3162]
- **Proteins:** TED4 (Plant heme oxygenase (decyclizing) family protein)
- **Chemicals:** cisplatin (PubChem CID 5460033)
- **Diseases:** lung cancer (MONDO:0005138), non-small cell lung cancer (MONDO:0005233)

## Full-text entities

- **Diseases:** lung cancer (MESH:D008175)
- **Chemicals:** cisplatin (MESH:D002945), tinzaparin (MESH:D000078222)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12934117/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12934117/full.md

---
Source: https://tomesphere.com/paper/PMC12934117